Xeris Biopharma Insider Deals Surge: Director Kong Garheng Buys 24,193 Restricted Shares, Fueling Investor Confidence and a 37.95% Year‑to‑Date Upswing

Insider Activity Highlights the Momentum Behind Xeris Biopharma

Xeris Biopharma Holdings has seen a surge of insider transactions in early June, with director Kong Garheng acquiring 24,193 restricted shares and 32,996 options on 4 June 2026. The moves came at a stable share price of $6.18, and the market’s reaction—an 88‑point buzz and +47 sentiment—suggests that investors are taking note of the firm’s growing confidence in its platform. The acquisition of a full block of restricted shares is a strong indicator that senior management believes the company’s valuation is on the rise, especially given Xeris’s 37.95 % year‑to‑date upside and its 106‑P/E ratio, which signals a valuation premium for a high‑growth biotech.

What the Deal Signals for Shareholders

Kong’s purchase is not an isolated event. The company’s recent insider activity shows a pattern of “buy‑first, sell‑later” trading: most insiders (including the likes of Marla Persky, Dawn Halkuff, and Barbara‑Jean Bormann‑Kennedy) have been adding to their positions in the past weeks, then selectively liquidating when the price peaks. This behavior suggests a bullish outlook—insiders are backing their own stock and only cashing in when the market rewards their confidence. For investors, the trend underscores a potential upside: as insiders continue to accumulate, the signal of future growth is reinforced, while the modest selling volume keeps liquidity manageable.

Kong Garheng’s Transaction Profile

Kong has been a steady participant in Xeris’s equity program since 2025, when he bought 50,000 shares at no cost under a restricted‑stock plan. In 2026, he repeated this pattern, adding another 24,193 shares in June. His transactions are almost always priced at zero or near zero, indicating that he is taking advantage of vesting grants rather than paying for shares outright. Historically, Kong’s holdings have grown from 214,144 to over 238,000 shares in less than a year, a 12 % increase that aligns with the company’s expansion of its injectables platform. His preference for restricted‑stock units (RSUs) rather than options reflects a risk‑averse stance, valuing guaranteed shares over the upside of options that may or may not vest.

Investor Takeaway

The current deal, combined with a broader insider accumulation trend, points to a management team that is confident in Xeris’s technology and market prospects. While the company’s valuation remains on the high side for the biotech sector, the pattern of insider buying—especially at zero cost—provides a positive signal for investors looking for a high‑growth play. As the company advances its injectables platform, the sustained insider interest may translate into continued share appreciation, making Xeris an intriguing candidate for portfolio inclusion in the coming quarter.